WeightWatchers is struggling. Launched in the early 1960s, the brand grew by helping members shed pounds through behavioural change programmes. Then, GLP-1 anti-obesity drugs hit the market, long-time spokesperson and board member Oprah Winfrey announced her departure, and the company’s credit rating was downgraded. FT reporter Anna Mutoh examines whether WeightWatchers’ latest strategy can produce the turnaround investors are hoping for.
Clip from Lionsgate Television
- - - - - - - - - - - - - - - - - - - - - - - - - -
For further reading:
WeightWatchers faces an era when weight loss comes in a syringe
Behold the Ozempic effect on business
The race to develop the next generation of weight-loss drugs
- - - - - - - - - - - - - - - - - - - - - - - - - -
On X, follow Anna Mutoh (@anna_mutoh) and Michela Tindera (@mtindera07), or follow Michela on LinkedIn for updates about the show and more.
Read a transcript of this episode on FT.com
Hosted on Acast. See acast.com/privacy for more information.
Introducing Behind the Money: Night School
Best Of: How Russia loots grain from Ukraine
Climate crisis: Who should pay to rebuild Pakistan?
Inside UBS’s takeover of Credit Suisse
Martin Wolf on why banks fail and what to do about it
Why SVB’s collapse is not a 2008 repeat
Tracking the mysterious rise of a UAE company
What’s causing the US airline chaos?
The costs of Russia’s invasion of Ukraine
Europe’s Big Tech trust buster
The US dollar loses its crown
What’s behind the job cuts in Big Tech?
China's reset
A turning point for Tesla?
Indonesia’s secret to economic success
What we can learn from 300-year-old bubbles
Martin Wolf on the economy in 2023
Credit Suisse's last chance
Best Of: Why VC funding is drying up
Qatar’s $200bn bet on the World Cup
Create your
podcast in
minutes
It is Free
The emPOWERed Half Hour
FT News Briefing
Money Clinic with Claer Barrett
FT World Weekly
FT News in Focus
FT Banking Weekly